PPARs, RXRs, and Stem CellsView this Special Issue
Research Article | Open Access
K. R. Shockley, C. J. Rosen, G. A. Churchill, B. Lecka-Czernik, "PPAR2 Regulates a Molecular Signature of Marrow Mesenchymal Stem Cells", PPAR Research, vol. 2007, Article ID 081219, 13 pages, 2007. https://doi.org/10.1155/2007/81219
PPAR2 Regulates a Molecular Signature of Marrow Mesenchymal Stem Cells
Bone formation and hematopoiesis are anatomically juxtaposed and share common regulatory mechanisms. Bone marrow mesenchymal stromal/stem cells (MSC) contain a compartment that provides progeny with bone forming osteoblasts and fat laden adipocytes as well as fibroblasts, chondrocytes, and muscle cells. In addition, marrow MSC provide an environment for support of hematopoiesis, including the development of bone resorbing osteoclasts. The PPAR2 nuclear receptor is an adipocyte-specific transcription factor that controls marrow MSC lineage allocation toward adipocytes and osteoblasts. Increased expression of PPAR2 with aging correlates with changes in the MSC status in respect to both their intrinsic differentiation potential and production of signaling molecules that contribute to the formation of a specific marrow microenvironment. Here, we investigated the effect of PPAR2 on MSC molecular signature in respect to the expression of gene markers associated exclusively with stem cell phenotype, as well as genes involved in the formation of a stem cell supporting marrow environment. We found that PPAR2 is a powerful modulator of stem cell-related gene expression. In general, PPAR2 affects the expression of genes specific for the maintenance of stem cell phenotype, including LIF, LIF receptor, Kit ligand, SDF-1, Rex-1/Zfp42, and Oct-4. Moreover, the antidiabetic PPAR agonist TZD rosiglitazone specifically affects the expression of “stemness” genes, including ABCG2, Egfr, and CD44. Our data indicate that aging and antidiabetic TZD therapy may affect mesenchymal stem cell phenotype through modulation of PPAR2 activity. These observations may have important therapeutic consequences and indicate a need for more detailed studies of PPAR2 role in stem cell biology.
- E. D. Rosen and B. M. Spiegelman, “PPAR: a nuclear regulator of metabolism, differentiation, and cell growth,” Journal of Biological Chemistry, vol. 276, no. 41, pp. 37731–37734, 2001.
- Y. Zhu, C. Qi, J. R. Korenberg et al., “Structural organization of mouse peroxisome proliferator-activated receptor (mPPAR) gene: alternative promoter use and different splicing yield two mPPAR isoforms,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 17, pp. 7921–7925, 1995.
- L. Fajas, D. Auboeuf, E. Raspé et al., “The organization, promoter analysis, and expression of the human PPAR gene,” Journal of Biological Chemistry, vol. 272, no. 30, pp. 18779–18789, 1997.
- L. Fajas, J.-C. Fruchart, and J. Auwerx, “PPAR3 mRNA: a distinct PPAR mRNA subtype transcribed from an independent promoter,” FEBS Letters, vol. 438, no. 1-2, pp. 55–60, 1998.
- Y. Chen, A. R. Jimenez, and J. D. Medh, “Identification and regulation of novel PPAR- splice variants in human THP-1 macrophages,” Biochimica et Biophysica Acta, vol. 1759, no. 1-2, pp. 32–43, 2006.
- D. Yamashita, T. Yamaguchi, M. Shimizu, N. Nakata, F. Hirose, and T. Osumi, “The transactivating function of peroxisome proliferator-activated receptor is negatively regulated by SUMO conjugation in the amino-terminal domain,” Genes to Cells, vol. 9, no. 11, pp. 1017–1029, 2004.
- D. Ren, T. N. Collingwood, E. J. Rebar, A. P. Wolffe, and H. S. Camp, “PPAR knockdown by engineered transcription factors: exogenous PPAR2 but not PPAR1 reactivates adipogenesis,” Genes and Development, vol. 16, no. 1, pp. 27–32, 2002.
- B. Lecka-Czernik, I. Gubrij, E. J. Moerman et al., “Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPAR2,” Journal of Cellular Biochemistry, vol. 74, no. 3, pp. 357–371, 1999.
- M. Ashburner, C. A. Ball, J. A. Blake et al., “Gene ontology: tool for the unification of biology,” Nature Genetics, vol. 25, no. 1, pp. 25–29, 2000.
- Y. Jiang, B. N. Jahagirdar, R. L. Reinhardt et al., “Pluripotency of mesenchymal stem cells derived from adult marrow,” Nature, vol. 418, no. 6893, pp. 41–49, 2002.
- P. Bianco, M. Riminucci, S. Gronthos, and P. G. Robey, “Bone marrow stromal stem cells: nature, biology, and potential applications,” Stem Cells, vol. 19, no. 3, pp. 180–192, 2001.
- J. E. Aubin, “Regulation of osteoblast formation and function,” Reviews in Endocrine and Metabolic Disorders, vol. 2, no. 1, pp. 81–94, 2001.
- T. Akune, S. Ohba, S. Kamekura et al., “PPAR insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors,” Journal of Clinical Investigation, vol. 113, no. 6, pp. 846–855, 2004.
- M. J. Jeon, J. A. Kim, S. H. Kwon et al., “Activation of peroxisome proliferator-activated receptor- inhibits the Runx2-mediated transcription of osteocalcin in osteoblasts,” Journal of Biological Chemistry, vol. 278, no. 26, pp. 23270–23277, 2003.
- E. J. Moerman, K. Teng, D. A. Lipschitz, and B. Lecka-Czernik, “Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-2 transcription factor and TGF-/BMP signaling pathways,” Aging Cell, vol. 3, no. 6, pp. 379–389, 2004.
- S. O. Rzonca, L. J. Suva, D. Gaddy, D. C. Montague, and B. Lecka-Czernik, “Bone is a target for the antidiabetic compound rosiglitazone,” Endocrinology, vol. 145, no. 1, pp. 401–406, 2004.
- V. Sottile, K. Seuwen, and M. Kneissel, “Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPAR agonist BRL49653 (rosiglitazone),” Calcified Tissue International, vol. 75, no. 4, pp. 329–337, 2004.
- M. A. Sorocéanu, D. Miao, X.-Y. Bai, H. Su, D. Goltzman, and A. C. Karaplis, “Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis,” Journal of Endocrinology, vol. 183, no. 1, pp. 203–216, 2004.
- T.-A. Cock, J. Back, F. Elefteriou et al., “Enhanced bone formation in lipodystrophic PPAR mice relocates haematopoiesis to the spleen,” EMBO Reports, vol. 5, no. 10, pp. 1007–1012, 2004.
- A. A. Ali, R. S. Weinstein, S. A. Stewart, A. M. Parfitt, S. C. Manolagas, and R. L. Jilka, “Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation,” Endocrinology, vol. 146, no. 3, pp. 1226–1235, 2005.
- O. P. Lazarenko, S. O. Rzonca, W. R. Hogue, F. L. Swain, L. J. Suva, and B. Lecka-Czernik, “Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone,” Endocrinology, vol. 148, no. 6, pp. 2669–2680, 2007.
- A. V. Schwartz, D. E. Sellmeyer, E. Vittinghoff et al., “Thiazolidinedione use and bone loss in older diabetic adults,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 9, pp. 3349–3354, 2006.
- A. Grey, M. Bolland, G. Gamble et al., “The peroxisome proliferator-activated receptor- agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 4, pp. 1305–1310, 2007.
- S. E. Kahn, S. M. Haffner, M. A. Heise et al., “Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy,” New England Journal of Medicine, vol. 355, no. 23, pp. 2427–2443, 2006.
- Y. Li and M. A. Lazar, “Differential gene regulation by PPAR agonist and constitutively active PPAR2,” Molecular Endocrinology, vol. 16, no. 5, pp. 1040–1048, 2002.
- D. L. Gerhold, F. Liu, G. Jiang et al., “Gene expression profile of adipocyte differentiation and its regulation by peroxisome proliferator-activated receptor- agonists,” Endocrinology, vol. 143, no. 6, pp. 2106–2118, 2002.
- S. Yu, K. Matsusue, P. Kashireddy et al., “Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor 1 (PPAR1) overexpression,” Journal of Biological Chemistry, vol. 278, no. 1, pp. 498–505, 2003.
- B. Lecka-Czernik, C. Ackert-Bicknell, M. L. Adamo et al., “Activation of peroxisome proliferator-activated receptor (PPAR) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo,” Endocrinology, vol. 148, no. 2, pp. 903–911, 2007.
- B. Lecka-Czernik, E. J. Moerman, D. F. Grant, J. M. Lehmann, S. C. Manolagas, and R. L. Jilka, “Divergent effects of selective peroxisome proliferator-activated receptor-2 ligands on adipocyte versus osteoblast differentiation,” Endocrinology, vol. 143, no. 6, pp. 2376–2384, 2002.
- J. B. Mitchell, K. McIntosh, S. Zvonic et al., “Immunophenotype of human adipose-derived cells: temporal changes in stromal-associated and stem cell-associated markers,” Stem Cells, vol. 24, no. 2, pp. 376–385, 2006.
- A. J. Katz, A. Tholpady, S. S. Tholpady, H. Shang, and R. C. Ogle, “Cell surface and transcriptional characterization of human adipose-derived adherent stromal (hADAS) cells,” Stem Cells, vol. 23, no. 3, pp. 412–423, 2005.
- N. B. Ivanova, J. T. Dimos, C. Schaniel, J. A. Hackney, K. A. Moore, and I. R. Lemischka, “A stem cell molecutar signature,” Science, vol. 298, no. 5593, pp. 601–604, 2002.
- M. Ramalho-Santos, S. Yoon, Y. Matsuzaki, R. C. Mulligan, and D. A. Melton, ““Stemness”: transcriptional profiling of embryonic and adult stem cells,” Science, vol. 298, no. 5593, pp. 597–600, 2002.
- Superarray Bioscience Corporation, “Oligo GEArray; Mouse Stem Cell Microarray,” 2006.
- M. Tavassoli, “Fatty involution of marrow and the role of adipose tissue in hematopoiesis,” in Handbook of the Hematopoietic Microenvironment, M. Tavassoli, Ed., pp. 157–187, Humana Press, Clifton, NJ, USA, 1989.
- J. M. Gimble, M.-A. Dorheim, Q. Cheng et al., “Response of bone marrow stromal cells to adipogenic antagonists,” Molecular and Cellular Biology, vol. 9, no. 11, pp. 4587–4595, 1989.
- M. Tavassoli, “Marrow adipose cells and hemopoiesis: an interpretative review,” Experimental Hematology, vol. 12, no. 2, pp. 139–146, 1984.
- O. Kajkenova, B. Lecka-Czernik, I. Gubrij et al., “Increased adipogenesis and myelopoiesis in the bone marrow of SAMP6, a murine model of defective osteoblastogenesis and low turnover osteopenia,” Journal of Bone and Mineral Research, vol. 12, no. 11, pp. 1772–1779, 1997.
- M. Z. Ratajczak, E. Zuba-Surma, M. Kucia, R. Reca, W. Wojakowski, and J. Ratajczak, “The pleiotropic effects of the SDF-1-CXCR4 axis in organogenesis, regeneration and tumorigenesis,” Leukemia, vol. 20, no. 11, pp. 1915–1924, 2006.
- S. Gronthos and A. C. W. Zannettino, “The role of the chemokine CXCL12 in osteoclastogenesis,” Trends in Endocrinology and Metabolism, vol. 18, no. 3, pp. 108–113, 2007.
- O. Voiculescu, P. Charnay, and S. Schneider-Maunoury, “Expression pattern of a Krox-20/Cre knock-in allele in the developing hindbrain, bones, and peripheral nervous system,” Genesis, vol. 26, no. 2, pp. 123–126, 2000.
- N. Leclerc, T. Noh, A. Khokhar, E. Smith, and B. Frenkel, “Glucocorticoids inhibit osteocalcin transcription in osteoblasts by suppressing Egr2/Krox20-binding enhancer,” Arthritis and Rheumatism, vol. 52, no. 3, pp. 929–939, 2005.
- N. P. Mongan, K. M. Martin, and L. J. Gudas, “The putative human stem cell marker, Rex-1 (Zfp42): structural classification and expression in normal human epithelial and carcinoma cell cultures,” Molecular Carcinogenesis, vol. 45, no. 12, pp. 887–900, 2006.
- J.-Z. Zhang, W. Gao, H.-B. Yang, B. Zhang, Z.-Y. Zhu, and Y.-F. Xue, “Screening for genes essential for mouse embryonic stem cell self-renewal using a subtractive RNA interference library,” Stem Cells, vol. 24, no. 12, pp. 2661–2668, 2006.
- S. Zhou, J. D. Schuetz, K. D. Bunting et al., “The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype,” Nature Medicine, vol. 7, no. 9, pp. 1028–1034, 2001.
- C. Hirschmann-Jax, A. E. Foster, G. G. Wulf et al., “A distinct “side population” of cells with high drug efflux capacity in human tumor cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 39, pp. 14228–14233, 2004.
- R. W. C. Wong, “Transgenic and knock-out mice for deciphering the roles of EGFR ligands,” Cellular and Molecular Life Sciences, vol. 60, no. 1, pp. 113–118, 2003.
- M. Pesce and H. R. Schöler, “Oct-4: gatekeeper in the beginnings of mammalian development,” Stem Cells, vol. 19, no. 4, pp. 271–278, 2001.
- D. G. Simmons and J. C. Cross, “Determinants of trophoblast lineage and cell subtype specification in the mouse placenta,” Developmental Biology, vol. 284, no. 1, pp. 12–24, 2005.
Copyright © 2007 K. R. Shockley et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.